Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research
Lifeward (Nasdaq: LFWD) has appointed Dr. Keith E. Tansey as Consulting Director of Clinical Research. With over 30 years of experience in spinal cord injury research and treatment, Dr. Tansey brings valuable expertise to Lifeward's Medical Affairs team. His responsibilities include developing the company's clinical research program, advancing key opinion leader opportunities, and supporting clinical partnerships to expand the use of personal exoskeletons for individuals with spinal cord injuries.
Dr. Tansey, a Professor at the University of Mississippi Medical Center and a Physician Scientist at the Veterans Administration Medical Center, is board-certified in Neurology with subspecialty certifications in Spinal Cord Injury Medicine and Neural Repair and Rehabilitation. His appointment aligns with Lifeward's mission to improve the lives of individuals with physical limitations or disabilities through innovative rehabilitation solutions.
Lifeward (Nasdaq: LFWD) ha nominato Dr. Keith E. Tansey come Direttore Consulente della Ricerca Clinica. Con oltre 30 anni di esperienza nella ricerca e trattamento delle lesioni del midollo spinale, il Dr. Tansey porta un prezioso bagaglio di competenze al team degli Affari Medicali di Lifeward. Le sue responsabilità includono lo sviluppo del programma di ricerca clinica dell'azienda, l'avanzamento delle opportunità con i leader di pensiero e il supporto delle partnership cliniche per espandere l'uso dei esoscheletri personali per le persone con lesioni spinali.
Il Dr. Tansey, Professore presso il Centro Medico dell'Università del Mississippi e Ricercatore Medico presso il Centro Medico dell'Amministrazione degli Veterani, è certificato dal consiglio in Neurologia con certificazioni di sottospecialità in Medicina delle Lesioni del Midollo Spinale e Riparazione e Riabilitazione Neurale. La sua nomina si allinea con la missione di Lifeward di migliorare la vita delle persone con limitazioni fisiche o disabilità attraverso soluzioni innovative di riabilitazione.
Lifeward (Nasdaq: LFWD) ha nombrado al Dr. Keith E. Tansey como Director Consultor de Investigación Clínica. Con más de 30 años de experiencia en investigación y tratamiento de lesiones de médula espinal, el Dr. Tansey aporta una valiosa experiencia al equipo de Asuntos Médicos de Lifeward. Sus responsabilidades incluyen el desarrollo del programa de investigación clínica de la compañía, el avance de oportunidades con líderes de opinión y el apoyo a las asociaciones clínicas para expandir el uso de exoesqueletos personales para individuos con lesiones en la médula espinal.
El Dr. Tansey, profesor en el Centro Médico de la Universidad de Misisipi y científico médico en el Centro Médico de la Administración de Veteranos, está certificado en Neurología con certificaciones de subespecialidad en Medicina de Lesiones de Médula Espinal y Reparación y Rehabilitación Neural. Su nombramiento se alinea con la misión de Lifeward de mejorar la vida de las personas con limitaciones físicas o discapacidades a través de soluciones innovadoras de rehabilitación.
Lifeward (Nasdaq: LFWD)는 Dr. Keith E. Tansey를 임상 연구의 컨설팅 이사로 임명했습니다. 척수 손상 연구 및 치료 분야에서 30년 이상의 경험을 가진 Tansey 박사는 Lifeward의 의료 업무 팀에 귀중한 전문 지식을 제공합니다. 그의 책임은 회사의 임상 연구 프로그램 개발, 주요 의견 지도자 기회의 진전 및 척수 손상 환자를 위한 개인용 외골격 사용 확대를 위한 임상 파트너십 지원을 포함합니다.
Tansey 박사는 미시시피 대학 의료 센터의 교수이자 재향 군인 관리 의료 센터의 의과학자로, 신경학 전문의로 인증되어 있으며, 척수 손상 의학 및 신경 회복 및 재활의 하위 전문 인증을 보유하고 있습니다. 그의 임명은 혁신적인 재활 솔루션을 통해 신체적 제한이나 장애가 있는 사람들의 삶을 개선하려는 Lifeward의 사명과 일치합니다.
Lifeward (Nasdaq: LFWD) a nommé Dr. Keith E. Tansey en tant que Directeur Consultant de la Recherche Clinique. Fort de plus de 30 ans d'expérience dans la recherche et le traitement des lésions de la moelle épinière, le Dr. Tansey apporte une expertise précieuse à l'équipe des Affaires Médicales de Lifeward. Ses responsabilités comprennent le développement du programme de recherche clinique de l'entreprise, la promotion des opportunités de leaders d'opinion et le soutien des partenariats cliniques pour élargir l'utilisation des exosquelettes personnels pour les personnes souffrant de lésions de la moelle épinière.
Le Dr. Tansey, professeur au Centre Médical de l'Université du Mississippi et scientifique médical au Centre Médical de l'Administration des Anciens Combattants, est certifié en neurologie avec des certifications de sous-spécialité en médecine des lésions de la moelle épinière et en réparation et réhabilitation neurale. Sa nomination s'inscrit dans la mission de Lifeward d'améliorer la vie des personnes présentant des limitations physiques ou des handicaps grâce à des solutions de réhabilitation innovantes.
Lifeward (Nasdaq: LFWD) hat Dr. Keith E. Tansey zum Beratenden Direktor der klinischen Forschung ernannt. Mit über 30 Jahren Erfahrung in der Forschung und Behandlung von Rückenmarksverletzungen bringt Dr. Tansey wertvolle Expertise in das medizinische Team von Lifeward ein. Zu seinen Aufgaben gehört die Entwicklung des klinischen Forschungsprogramms des Unternehmens, das Vorantreiben von Möglichkeiten mit Meinungsführern und die Unterstützung klinischer Partnerschaften, um die Nutzung von persönlichen Exoskeletten für Personen mit Rückenmarksverletzungen auszubauen.
Dr. Tansey ist Professor am Universitätsmedizinischen Zentrum von Mississippi und Arztwissenschaftler am Medizinischen Zentrum der Veteranenverwaltung. Er ist im Bereich Neurologie zertifiziert und hat zusätzliche Fachzertifikate in der Medizin der Rückenmarksverletzungen sowie in der Neuralen Reparatur und Rehabilitation. Seine Ernennung steht im Einklang mit der Mission von Lifeward, das Leben von Menschen mit körperlichen Einschränkungen oder Behinderungen durch innovative Rehabilitationslösungen zu verbessern.
- Appointment of Dr. Keith E. Tansey, a highly experienced and respected expert in spinal cord injury research
- Potential for expansion of personal exoskeleton use through clinical partnerships
- Alignment with company's mission to improve lives of individuals with physical limitations
- None.
A past-president of the American Spinal Injury Association, Dr. Tansey brings Lifeward over 30 years of experience in research and treatment of spinal cord injuries as a practicing Physician, Professor, and Research Scientist
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced that Dr. Keith E. Tansey, MD, PhD, will be joining its Medical Affairs team as a consultant in the role of Director, Clinical Research. Dr. Tansey’s responsibilities will include the development and stewardship of Lifeward’s clinical research program, the advancement of key opinion leader opportunities, and identifying and supporting clinical partnerships to expand the use of personal exoskeletons for individuals with spinal cord injuries.
Larry Jasinski, Lifeward’s Chief Executive Officer, commented on the occasion, “In addition to his significant clinical credentials and expertise, Dr. Tansey brings with him a devotion to advancing the field of spinal cord injury management and rehabilitation. Dr. Tansey’s experience over a 30-year career is perfectly aligned with Lifeward’s mission to expand access and utilization of personal exoskeletons to improve the lives of individuals living with physical limitations or disability.”
Keith E. Tansey, MD, PhD, FASNR, FASIA, is currently a Professor in the Department of Neurosurgery at the University of Mississippi Medical Center and a Physician Scientist on the Spinal Cord Injury Medicine and Research Services at the Veterans Administration Medical Center in Jackson Mississippi, USA. He is a board-certified Neurologist with subspecialty certifications in Spinal Cord Injury Medicine and Neural Repair and Rehabilitation. Dr. Tansey’s career and work spans 30 years and includes work on several committees, advisory boards, and organizations such as the International Society for Restorative Neurology (Past-President), the American Society for Neurorehabilitation (Fellow), and the American Spinal Injury Association (Past-President and Fellow). Included amongst his numerous accolades and accomplishments, Dr. Tansey guided efforts for the latest revision of the International Standards for Neurological Classification of Spinal Cord Injury.
“I’m truly impressed with the advancements that Lifeward has brought forth to the field of spinal cord injury medicine and rehabilitation,” said Dr. Tansey. “I look forward to this exciting period of growth and execution which builds upon all the foundational work that the team at Lifeward has accomplished to date. I am thrilled to play a role in expanding utilization of personal exoskeletons to advance the standard of care for individuals living with spinal cord injury.”
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit GoLifeward.com.
ReWalk®, ReStore® and Alter G® are registered trademarks of ReWalk Robotics Ltd. (DBA Lifeward) and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding the Company’s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek," and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Lifeward’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in the Company’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading "Risk Factors" in the Company’s annual report on Form 10-K and 10-K/A, as amended, for the year ended December 31, 2023 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, Lifeward undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Lifeward Media Contact:
Kathleen O’Donnell
VP Marketing & New Business Development
Lifeward
E: media@golifeward.com
Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward
E: ir@golifeward.com
FAQ
Who is Dr. Keith E. Tansey and what role will he play at Lifeward (LFWD)?
What are Dr. Tansey's credentials and how do they benefit Lifeward (LFWD)?
How might Dr. Tansey's appointment impact Lifeward's (LFWD) clinical research and market position?
